Waldhäuser Str. 64
72076 Tübingen, de
Biametrics Successfully Finalizes Feasibility Study with MorphoSys in the Area of High-Throughput Antibody Screening
Biametrics performed a very successful screening study using MorphoSys' reagents and Biametrics' label-free microarray based instrumentation b-screen for the characterization of Fab fragment antigen interactions. The feasibility study clearly demonstrated the advantages of b-screen to speed up the overall antibody screening process using the microarray format. Recently, Biametrics launched their b-screen device for high-throughput biomolecular interaction screening/analysis.
"We are delighted to be collaborating with MorphoSys, a leader in the development of biotherapeutics," said Dr. Florian Pröll, Managing Director of Biametrics "We look forward to expand our collaboration in the field of biomolecular interaction analysis."
Biametrics' b-screen device enables the detection of these biomolecules in a high-density array format on microscope slide disposables. Thereby, no fluorescence labels are needed for read-out. This leads to minimized sample pre-treatment and reagent consumption. With this new optical detection method, it is possible to reduce the complexity of the conventional label-free assays while enhancing the throughput and maintaining precision and reliability.
"We have identified b-screen as an promising technology in the field of epitope mapping, and will now broaden our collaboration with Biametrics", added Dr. Markus Enzelberger, Senior VP, Head of Discovery Alliances & Technologies at MorphoSys AG.
The collaboration between MorphoSys AG as a globally established supplier of therapeutic antibodies and Biametrics as an aspiring technology company allows for a fast and successful development of such biopharmaceuticals. MorphoSys will continue the cooperation with Biametrics.
About MorphoSys AG
MorphoSys developed HuCAL, the most successful antibody library technology in the pharmaceutical industry. By successfully applying this and other patented technologies, MorphoSys has become a leader in the field of therapeutic antibodies, one of the fastest-growing drug classes in human healthcare.
Together with its pharmaceutical partners, MorphoSys has built a therapeutic pipeline of more than 80 human antibody drug candidates for the treatment of cancer, rheumatoid arthritis, and Alzheimer’s disease, to name just a few. With its ongoing commitment to new antibody technology and drug development, MorphoSys is focused on making the healthcare products of tomorrow. MorphoSys is listed on the Frankfurt Stock Exchange under the symbol MOR. For regular updates about MorphoSys, visit http://www.morphosys.com.
The use of information published here for personal information and editorial processing is generally free of charge. Please clarify any copyright issues with the stated publisher before further use. In the event of publication, please send a specimen copy to firstname.lastname@example.org.